Hims & Hers Health officer Boughton Soleil sold 6,236 shares at $27.86 each, a transaction equal to about 2.0% of the prior holding. The disclosed post-sale balance was 304,270 shares, giving investors the specific ownership figure and scale of the reported insider transaction.
Key Highlights
- Boughton Soleil held 304,270 Hims & Hers Health shares after the transaction.
- The sale represented about 2.0% of Soleil’s prior share holding.
- The transaction used SEC code S, which denotes a sale.
Boughton Soleil sold 6,236 Hims & Hers Health (NYSE: HIMS) shares at $27.86 per share on 16 September 2026. The transaction involved the company’s Chief Legal Officer.
6,236 Shares Sold at $27.86
The transaction was recorded under SEC code S, which identifies a sale. The reported price was $27.86 for each share transferred. The transaction date was 16 September 2026. The sale involved 6,236 shares. Hims & Hers Health is the named company connected to the transaction.
Post-Transaction Ownership Stood at 304,270 Shares
The transaction represented about 2.0% of Soleil’s prior share holding. The 2.0% measure is tied to the holding before the sale, while 304,270 shares is the disclosed balance afterward.
FAQs
Q: How many Hims & Hers Health shares did Boughton Soleil sell?
A: Boughton Soleil sold 6,236 Hims & Hers Health shares. The sale was priced at $27.86 per share on 16 September 2026.
Q: How did the insider sale affect Boughton Soleil’s HIMS ownership?
A: Boughton Soleil owned 304,270 Hims & Hers Health shares after the transaction. The sale represented about 2.0% of the prior share holding.
Q: What does SEC transaction code S mean for the Hims & Hers Health transaction?
A: SEC code S identifies a sale transaction. In this case, Boughton Soleil sold 6,236 shares of Hims & Hers Health at $27.86 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.